ERBB2 and breast cancer: Interestingly, patients with HER2+ breast cancer (16% of population, none treated with trastuzumab) did appear to derive greater benefit from the addition of anthracycline to P (HER2+: ACP vs P [HR, 1.85; 95% CI, 1.15–2.98]).